FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306168216> ?p ?o ?g. }

• W4306168216 abstract "To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA).One-year data from Italian subjects enrolled in the PsABio study (PsA patients receiving 1st- to 3rd-line treatment with ustekinumab or TNFi) were evaluated. Treatment persistence was analysed using Kaplan-Meier curves; hazard ratios (HR) of stopping treatment, and the corresponding 95% confidence intervals (CI), were computed through Cox regression models. Proportions of patients reaching clinical effectiveness endpoints were analysed using logistic regression, including propensity score (PS) adjustment for imbalanced baseline covariates, and non-response imputation if treatment was stopped/switched.Among 222 participants with follow-up data (effectiveness set), 101 received ustekinumab and 121 TNFi. In the ustekinumab group, 74.3% continued treatment up to 12±3 months compared to 63.6% in the TNFi group. Ustekinumab showed better persistence than TNFi, overall and in specific subgroups (females, monotherapy without methotrexate, BMI <25 or >30 kg/m2, patients receiving ustekinumab as 2nd-line treatment instead of a second TNFi). Overall, the PS-adjusted HR of treatment discontinuation was 0.46 (95% CI: 0.26-0.82) for ustekinumab vs. TNFi. cDAPSA LDA/remission was achieved in 43.5% of ustekinumab and 43.6% of TNFi-treated patients, while MDA was achieved in 24.2% and 28.0% of patients, respectively. After PS adjustment, odds ratios of clinical effectiveness did not differ significantly. Both treatments showed an acceptable safety profile.This prospective, real-life study found a better persistence of ustekinumab than TNFi in PsA patients. At 1 year, both treatments showed similar effectiveness." @default.
• W4306168216 created "2022-10-14" @default.
• W4306168216 creator A5003030575 @default.
• W4306168216 creator A5011583819 @default.
• W4306168216 creator A5013138894 @default.
• W4306168216 creator A5015866814 @default.
• W4306168216 creator A5016612107 @default.
• W4306168216 creator A5020328511 @default.
• W4306168216 creator A5034172837 @default.
• W4306168216 creator A5046575727 @default.
• W4306168216 creator A5047413454 @default.
• W4306168216 creator A5051526168 @default.
• W4306168216 creator A5057705176 @default.
• W4306168216 creator A5057958762 @default.
• W4306168216 creator A5066602987 @default.
• W4306168216 creator A5072819283 @default.
• W4306168216 creator A5075263979 @default.
• W4306168216 creator A5075546098 @default.
• W4306168216 creator A5085074461 @default.
• W4306168216 creator A5085647114 @default.
• W4306168216 creator A5088320250 @default.
• W4306168216 creator A5090231742 @default.
• W4306168216 date "2022-03-09" @default.
• W4306168216 modified "2023-09-30" @default.
• W4306168216 title "Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort" @default.
• W4306168216 doi "https://doi.org/10.55563/clinexprheumatol/j33pjt" @default.
• W4306168216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36226614" @default.
• W4306168216 hasPublicationYear "2022" @default.
• W4306168216 type Work @default.
• W4306168216 citedByCount "0" @default.
• W4306168216 crossrefType "journal-article" @default.
• W4306168216 hasAuthorship W4306168216A5003030575 @default.
• W4306168216 hasAuthorship W4306168216A5011583819 @default.
• W4306168216 hasAuthorship W4306168216A5013138894 @default.
• W4306168216 hasAuthorship W4306168216A5015866814 @default.
• W4306168216 hasAuthorship W4306168216A5016612107 @default.
• W4306168216 hasAuthorship W4306168216A5020328511 @default.
• W4306168216 hasAuthorship W4306168216A5034172837 @default.
• W4306168216 hasAuthorship W4306168216A5046575727 @default.
• W4306168216 hasAuthorship W4306168216A5047413454 @default.
• W4306168216 hasAuthorship W4306168216A5051526168 @default.
• W4306168216 hasAuthorship W4306168216A5057705176 @default.
• W4306168216 hasAuthorship W4306168216A5057958762 @default.
• W4306168216 hasAuthorship W4306168216A5066602987 @default.
• W4306168216 hasAuthorship W4306168216A5072819283 @default.
• W4306168216 hasAuthorship W4306168216A5075263979 @default.
• W4306168216 hasAuthorship W4306168216A5075546098 @default.
• W4306168216 hasAuthorship W4306168216A5085074461 @default.
• W4306168216 hasAuthorship W4306168216A5085647114 @default.
• W4306168216 hasAuthorship W4306168216A5088320250 @default.
• W4306168216 hasAuthorship W4306168216A5090231742 @default.
• W4306168216 hasBestOaLocation W43061682162 @default.
• W4306168216 hasConcept C126322002 @default.
• W4306168216 hasConcept C156957248 @default.
• W4306168216 hasConcept C197934379 @default.
• W4306168216 hasConcept C203014093 @default.
• W4306168216 hasConcept C207103383 @default.
• W4306168216 hasConcept C2776260265 @default.
• W4306168216 hasConcept C2777011040 @default.
• W4306168216 hasConcept C2777077863 @default.
• W4306168216 hasConcept C2777575956 @default.
• W4306168216 hasConcept C2778375690 @default.
• W4306168216 hasConcept C2778715236 @default.
• W4306168216 hasConcept C2778975655 @default.
• W4306168216 hasConcept C2780132546 @default.
• W4306168216 hasConcept C2780564577 @default.
• W4306168216 hasConcept C44249647 @default.
• W4306168216 hasConcept C71924100 @default.
• W4306168216 hasConceptScore W4306168216C126322002 @default.
• W4306168216 hasConceptScore W4306168216C156957248 @default.
• W4306168216 hasConceptScore W4306168216C197934379 @default.
• W4306168216 hasConceptScore W4306168216C203014093 @default.
• W4306168216 hasConceptScore W4306168216C207103383 @default.
• W4306168216 hasConceptScore W4306168216C2776260265 @default.
• W4306168216 hasConceptScore W4306168216C2777011040 @default.
• W4306168216 hasConceptScore W4306168216C2777077863 @default.
• W4306168216 hasConceptScore W4306168216C2777575956 @default.
• W4306168216 hasConceptScore W4306168216C2778375690 @default.
• W4306168216 hasConceptScore W4306168216C2778715236 @default.
• W4306168216 hasConceptScore W4306168216C2778975655 @default.
• W4306168216 hasConceptScore W4306168216C2780132546 @default.
• W4306168216 hasConceptScore W4306168216C2780564577 @default.
• W4306168216 hasConceptScore W4306168216C44249647 @default.
• W4306168216 hasConceptScore W4306168216C71924100 @default.
• W4306168216 hasLocation W43061682161 @default.
• W4306168216 hasLocation W43061682162 @default.
• W4306168216 hasLocation W43061682163 @default.
• W4306168216 hasLocation W43061682164 @default.
• W4306168216 hasOpenAccess W4306168216 @default.
• W4306168216 hasPrimaryLocation W43061682161 @default.
• W4306168216 hasRelatedWork W2082225446 @default.
• W4306168216 hasRelatedWork W2235471063 @default.
• W4306168216 hasRelatedWork W2265435010 @default.
• W4306168216 hasRelatedWork W2397514925 @default.
• W4306168216 hasRelatedWork W2564603710 @default.
• W4306168216 hasRelatedWork W2811213036 @default.
• W4306168216 hasRelatedWork W2995648997 @default.
• W4306168216 hasRelatedWork W3101847676 @default.
• W4306168216 hasRelatedWork W4285040880 @default.
• W4306168216 hasRelatedWork W4385514506 @default.

• next